OncoMatch/Clinical Trials/NCT06775080
The Use of Propranolol in the Perioperative Period of Resectable Gastrointestinal Tumors
Is NCT06775080 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies propranolol (beta-blocker used treat high blood pressure) for gastrointestinal tumors.
Treatment: propranolol (beta-blocker used treat high blood pressure) — In this study, perioperative propranolol β-blockade was administered to patients with surgically resectable primary gastrointestinal tumors to explore the safety, efficacy, and alleviation of perioperative psychological stress. At the same time, a multi-omics study was conducted using clinical samples to explore the activation of anti-tumor immune response and its mechanism.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: surgery
Patients who have undergone surgery for GI tumors within the previous six months
Cannot have received: neoadjuvant chemotherapy
Patients receiving neoadjuvant chemotherapy prior to planned gastrointestinal tumor resection
Lab requirements
Kidney function
creatinine clearance ≤ 0.15 mmol/L
Liver function
AST or ALT or ALP ≤ 2.5x ULN, bilirubin ≤ 1.5x ULN
Cardiac function
Resting blood pressure > 100/60 mmHg, heart rate > 60 beats per minute; exclusion for pathological sinus node syndrome, sinus bradycardia (<60 bpm), AV block (any degree)
Resting blood pressure greater than 100/60mmHg, heart rate greater than 60 beats per minute. Pathological sinus node syndrome; Sinus bradycardia (less than 60 beats/minute); First, second or third degree AV block; Resting blood pressure less than 100/60 mmHg; Patients with renal insufficiency (defined as creatinine clearance greater than 0.15 mmol/L); Patients with hepatic insufficiency: AST or ALT or ALP > 2.5 times the upper limit of normal (ULN), bilirubin > 1.5 times the ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06775080 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgery, neoadjuvant chemotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages